(R)-2-(2-hydroxyphenylamino)-5,5-dimethyl-4,5-dihydrothiazole-4-carboxylic acid monohydrochloride | 1334385-87-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-2-(2-hydroxyphenylamino)-5,5-dimethyl-4,5-dihydrothiazole-4-carboxylic acid monohydrochloride
• 英文别名: Ebaresdax Hydrochloride；(4R)-2-(2-hydroxyanilino)-5,5-dimethyl-4H-1,3-thiazole-4-carboxylic acid;hydrochloride
• CAS: 1334385-87-3
• 化学式: C₁₂H₁₄N₂O₃S*ClH
• 分子量: 302.782
• InChiKey: LYYYTSUITXPVIS-SBSPUUFOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.56
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-(2-methoxyphenyl)cyanamide 在 盐酸 、 三溴化硼 作用下， 以 二氯甲烷 、 水 、 异丙醇 、 乙腈 为溶剂， 反应 2.25h， 生成 (R)-2-(2-hydroxyphenylamino)-5,5-dimethyl-4,5-dihydrothiazole-4-carboxylic acid monohydrochloride
  参考文献：
  名称：

  [EN] MANUFACTURING METHODS AND POLYMORPHS OF A THIAZOLINE ANTI-HYPERALGESIC AGENT
  [FR] PROCÉDÉS DE FABRICATION ET POLYMORPHES D'UN AGENT ANTI-HYPERALGÉSIQUE DE THIAZOLINE

  摘要：

  本文描述了制备一种硫氮杂环抗高痛觉化合物1及其多晶形式的方法。所述方法使用廉价试剂，并能够以商业规模提供化合物1。还提供了适用于人类使用的化合物1的制药组合物。(I)

  公开号：

  WO2020231496A1

文献信息

• Analgesic Compounds, Compositions, and Uses Thereof
  申请人：Mannion James C.

  公开号：US20110224269A1

  公开（公告）日：2011-09-15

  The invention relates to compounds, compositions, and methods for diminishing pain in a subject in need thereof comprising administering the compounds and compositions herein described.

  这项发明涉及化合物、组合物和方法，用于减轻需要的受试者的疼痛，包括给予所述的化合物和组合物。
• METHODS OF TREATING PAIN WITH A THIAZOLINE ANTI-HYPERALGESIC
  申请人：CERSCI THERAPEUTICS, INC.

  公开号：US20200246318A1

  公开（公告）日：2020-08-06

  Methods of treating diabetic neuropathic pain and post-surgical pain are provided. The methods include administering to an individual a therapeutically effective amount of a compound of Formula I (Compound 1). The method can be used to treat diabetic neuropathy arising from any type of nerve damage, and can also be used to treat post-surgical pain arising from any surgical procedure without the side effects associated with widely used analgesics such as opioids. Compound 1 can be formulated into many suitable dosage forms, including oral dosage forms such as tablets.

  本发明提供了治疗糖尿病神经病变性疼痛和术后疼痛的方法。该方法包括向个体施用化合物I (化合物1)的治疗有效量。该方法可用于治疗由于任何类型的神经损伤引起的糖尿病神经病变，还可用于治疗由任何手术程序引起的术后疼痛，而不会出现与广泛使用的镇痛药物如阿片类药物相关的副作用。化合物1可以制成许多适合的剂型，包括口服剂型如片剂。
• Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent
  申请人：ACADIA PHARMACEUTICALS INC.

  公开号：US11161826B2

  公开（公告）日：2021-11-02

  Provided herein are methods of making a thiazoline anti-hyperalgesic, Compound 1, and polymorphs thereof. The methods described herein use inexpensive reagents and are capable of providing Compound 1 in commercial-scale quantities. Also provided are pharmaceutical compositions of Compound 1 suitable for human administration.

  本文提供了制造噻唑啉类抗镇痛药化合物 1 及其多晶型物的方法。本文所述方法使用的试剂价格低廉，能够以商业规模提供化合物 1。此外，还提供了适合人体服用的化合物 1 药物组合物。
• METHODS OF TREATING DIABETIC NEUROPATHY WITH A THIAZOLINE ANTI-HYPERALGESIC AGENT
  申请人：CERSCI THERAPEUTICS, INC.

  公开号：US20200246317A1

  公开（公告）日：2020-08-06

  Methods of treating diabetic neuropathy and pain associated with diabetes are provided. The methods include administering to an individual a therapeutically effective amount of a compound of Formula I (Compound 1). The method can be used to treat diabetic neuropathy pain arising from type I or type II diabetes. Compound 1 can be formulated into many suitable dosage forms, including oral dosage forms such as tablets.
• METHODS OF TREATING POST-SURGICAL PAIN WITH A THIAZOLINE ANTI-HYPERALGESIC AGENT
  申请人：CERSCI THERAPEUTICS, INC.

  公开号：US20200246316A1

  公开（公告）日：2020-08-06

  Methods of treating post-surgical pain are provided. The methods include administering to an individual a therapeutically effective amount of a compound of Formula I (Compound 1). The method can be used to treat post-surgical pain arising from any surgical procedure without the side effects associated with widely used analgesics such as opioids. Compound 1 can be formulated into many suitable dosage forms, including oral dosage forms such as tablets.